Literature DB >> 2801838

Determination of cellular oncogene rearrangement or amplification in ovarian adenocarcinomas.

D M Smith1, D E Groff, R K Pokul, J L Bear, G Delgado.   

Abstract

Four cellular oncogenes, fos, myc, Ha-ras, and Ki-ras, are routinely expressed in ovarian adenocarcinomas. To determine whether the molecular lesion in ovarian carcinoma was a genetic rearrangement or amplification of expressed oncogenes, we examined the myc, Ha-ras, Ki-ras, and fos oncogenes in 14 serous adenocarcinomas of the ovary using molecular hybridization techniques. Using a series of diagnostic restriction endonucleases and gene-specific deoxyribonucleic acid probes, we found no evidence of rearrangement of these genes. In addition, we found no evidence of amplification of the cellular oncogenes analyzed in this series of ovarian tumors. Therefore genetic rearrangement or amplification of these cellular oncogenes is not the primary molecular lesion leading to their expression in ovarian carcinomas.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2801838     DOI: 10.1016/0002-9378(89)90750-3

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  3 in total

1.  Prognostic relevance of c-MYC gene amplification and polysomy for chromosome 8 in suboptimally-resected, advanced stage epithelial ovarian cancers: a Gynecologic Oncology Group study.

Authors:  Kathleen M Darcy; William E Brady; Jan K Blancato; Robert B Dickson; William J Hoskins; William P McGuire; Michael J Birrer
Journal:  Gynecol Oncol       Date:  2009-06-12       Impact factor: 5.482

Review 2.  c-MYC and Epithelial Ovarian Cancer.

Authors:  Jeyshka M Reyes-González; Pablo E Vivas-Mejía
Journal:  Front Oncol       Date:  2021-02-26       Impact factor: 6.244

3.  Expression of the zinc finger gene EVI-1 in ovarian and other cancers.

Authors:  D J Brooks; S Woodward; F H Thompson; B Dos Santos; M Russell; J M Yang; X Y Guan; J Trent; D S Alberts; R Taetle
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.